NCT01675024 - Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Healthy

Interventions

DRUG

Rotigotine, Period 1

"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"

DRUG

Rotigotine, Period 2

"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"

Trial Locations (1)

Unknown

Shanghai